

NEULAND LABORATORIES LIMITED


Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113, Road No. 2, Banjara Hills, Hyderabad - 500034

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2015

PART - I

Amount in Rs Lacs

Sl. No.	Particulars	Quarter Ended 30.09.2015 (Unaudited)	Quarter Ended 30.06.2015 (Unaudited)	Quarter Ended 30.09.2014 (Unaudited)	Half Year Ended 30.09.2015 (Unaudited)	Half Year Ended 30.09.2014 (Unaudited)	Year Ended 31.03.2015 (Audited)
1	Income from Operations						
	(a) Net Sales / Income from Operations	11,959.26	11,515.03	11,967.51	23,474.29	21,952.30	44,506.38
	(b) Other Operating Income	750.26	748.18	163.72	1,498.44	446.38	1,963.97
	Total Income from Operations (Net)	12,709.52	12,263.21	12,131.23	24,972.73	22,398.68	46,470.35
2	Expenses						
	(a) Consumption of Raw Materials	6,697.14	6,700.39	6,928.51	13,397.53	13,296.74	26,641.78
	(b) Changes in inventories of finished goods and work in process	108.75	(375.35)	(102.59)	(266.60)	(1,024.94)	(2,242.89)
	(c) Employee Benefit Expense	1,228.35	1,308.82	1,227.59	2,537.17	2,282.03	4,896.61
	(d) Depreciation	389.59	380.20	389.90	769.79	779.80	1,531.98
	(e) Manufacturing Expenses	1,402.96	1,444.13	1,600.09	2,847.09	2,841.60	5,563.22
	(f) Other Expenses	1,429.18	1,183.40	938.76	2,612.58	2,103.93	5,419.95
	Total Expenses	11,255.97	10,641.59	10,982.26	21,897.56	20,279.16	41,810.65
3	Profit from Operations before Other Income, Finance Costs and Exceptional Items (1-2)	1,453.55	1,621.62	1,148.97	3,075.17	2,119.52	4,659.70
4	Other Income	106.48	161.63	231.70	268.11	305.14	522.87
5	Profit from Ordinary Activities before Finance Costs and Exceptional Items (3+4)	1,560.03	1,783.25	1,380.67	3,343.28	2,424.66	5,182.57
6	Finance Costs	627.79	654.10	629.89	1,281.89	1,197.71	2,734.86
7	Profit from Ordinary Activities after Finance Costs but before Exceptional Items (5-6)	932.24	1,129.15	750.78	2,061.39	1,226.95	2,447.71
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	932.24	1,129.15	750.78	2,061.39	1,226.95	2,447.71
10	Tax Expense						
	(a) Current tax	409.41	475.68	178.60	885.09	282.50	671.38
	(b) Deferred Tax	(97.58)	(76.59)	164.65	(174.17)	338.48	198.20
	(c) MAT Credit entitlement	-	-	(107.21)	-	(211.11)	-
11	Net Profit from Ordinary Activities after Tax (9-10)	620.41	730.06	514.74	1,350.47	817.08	1,578.13
12	Extraordinary Items	-	-	-	-	-	-
13	Net Profit for the period (11-12)	620.41	730.06	514.74	1,350.47	817.08	1,578.13
14	Paid-up Equity Share Capital (Face Value Rs 10 per share)	895.39	895.39	772.86	895.39	772.86	895.39
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						15,010.27
16	Earnings per Share (EPS) (in Rs)						
	(a) Basic (Not Annualized)	6.98	8.22	6.21	15.20	9.76	18.47
	(b) Diluted (Not Annualized)	6.98	8.22	6.21	15.20	9.76	18.47



PART - II

Sl. No.	Particulars	Quarter Ended 30.09.2015	Quarter Ended 30.06.2015	Quarter Ended 30.09.2014	Half Year Ended 30.09.2015	Half Year Ended 30.09.2014	Year Ended 31.03.2015
A	PARTICULARS OF SHARE HOLDING						
1	Public Shareholding						
	(a) Number of Shares	42,91,506	42,87,627	38,25,199	42,91,506	38,25,199	42,87,627
	(b) Percentage of Shareholding	48.31%	48.27%	49.95%	48.31%	49.95%	48.27%
2	Promoters and Promoter Group Shareholding						
	(a) Pledged / Encumbered						
	-Number of Shares	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000	2,00,000
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	4.36%	4.35%	5.22%	4.36%	5.22%	4.35%
	-Percentage of Shares (as a % of the total share capital of the Company)	2.25%	2.25%	2.61%	2.25%	2.61%	2.25%
	(b) Non-encumbered						
	-Number of Shares	43,91,748	43,95,627	36,32,779	43,91,748	36,32,779	43,95,627
	-Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	95.64%	95.65%	94.78%	95.64%	94.78%	95.65%
	-Percentage of Shares (as a % of the total share capital of the Company)	49.44%	49.48%	47.44%	49.44%	47.44%	49.48%

B INVESTOR COMPLIANTS

Particulars	Quarter Ended 30.09.2015
Pending at the beginning of the quarter	0
Received during the quarter	12
Disposed off during the quarter	12
Remaining unresolved at the end of the quarter	0

NOTES:

- 1 The above unaudited financial results have been reviewed by the Audit Committee at their meeting held on October 28, 2015, and approved and taken on record at the Board of Directors meeting held on October 29, 2015.
- 2 EPS for quarter and six months ended 30 September, 2014 has been recomputed to adjust for the bonus element of rights issue completed during the financial year 2014-15, in accordance with the provisions of AS 20 - Earnings per Share.
- 3 The Company's operations are predominantly related to the manufacture of Active Pharmaceutical Ingredients (API). As such there is only one primary reportable segment as per Accounting Standard - AS 17 "Segment Reporting".



4 The statement of assets and liabilities is as follows:

SI No	Particulars	Amount in Rs Lacs	
		As on 30.09.2015 (Unaudited)	As on 31.03.2015 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	895.39	895.39
	(b) Reserves and Surplus	16,434.10	15,087.14
		17,329.49	15,982.53
2	Share Application Money Pending Allotment	-	-
3	Non-current Liabilities		
	(a) Long-term Borrowings	2,988.87	3,322.15
	(b) Deferred Tax Liability (Net)	1,050.38	1,224.55
	(c) Other Long-term Liabilities	273.00	273.00
	(d) Long-term Provisions	696.65	638.48
		5,008.90	5,458.18
4	Current Liabilities		
	(a) Short-term Borrowings	13,674.37	14,579.81
	(b) Trade Payables	12,343.28	11,396.60
	(c) Other Current Liabilities	2,747.65	3,095.49
	(d) Short-term Provisions	850.16	604.31
		29,615.46	29,676.21
	TOTAL	51,953.85	51,116.92
B	ASSETS		
1	Non-current Assets		
	(a) Fixed Assets	16,685.52	16,454.28
	(b) Non-current Investments	766.80	766.80
	(c) Long-term Loans and Advances	2,049.38	2,382.91
		19,501.70	19,603.99
2	Current Assets		
	(a) Inventories	12,209.69	11,340.40
	(b) Trade Receivables	12,736.87	12,884.83
	(c) Cash and Bank Balances	1,205.48	648.66
	(d) Short-term Loans and Advances	4,606.03	4,886.64
	(e) Other Current Assets	1,694.08	1,752.40
		32,452.15	31,512.93
	TOTAL	51,953.85	51,116.92

5 Previous quarter / year numbers have been regrouped wherever necessary.

Place: Hyderabad
Date: October 29, 2015



By Order of the Board
For Neuland Laboratories Limited



Dr. D.R. Rao
Chairman & Managing Director

DIN : 00107737

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
(Formerly Walker, Chandiook & Co)
7th Floor, Block III, White House
Kundan Bagh, Begumpet
Hyderabad 500016
India

T +91 40 6630 8200
F +91 40 6630 8230

Review Report

To the Board of Directors of Neuland Laboratories Limited

1. We have reviewed the accompanying statement of unaudited financial results (“the Statement”) of Neuland Laboratories Limited (“the Company”) for the quarter ended 30 September 2015 and the year to date results for the period 1 April 2015 to 30 September 2015, except for the disclosures regarding ‘Public Shareholding’ and ‘Promoter and Promoter Group Shareholding’ which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable accounting standards, as notified under the Companies (Accounting Standards) Rules, 2006 read with Rule 7 of the Companies (Accounts) Rules, 2014 in respect of Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Walker Chandiook & Co LLP
For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Sanjay Kumar Jain
per Sanjay Kumar Jain
Partner

Membership No.: 207660

Place: Hyderabad

Date: 29 October 2015

